Search

Your search keyword '"Rachmilewitz, E. A."' showing total 370 results
Start Over Author "Rachmilewitz, E. A."
370 results on '"Rachmilewitz, E. A."'

8. Molecular Follow-Up of Disease Progression and Interferon Therapy in Chronic Myelocytic Leukemia

Author

Ben-Yehuda, D., Krichevsky, S., Rachmilewitz, E. A., Avraham, A., Palumbo, G. A., Francesco Frassoni, Sahar, D., Rosenbaum, H., Paltiel, O., Zion, M., and Ben-Neriah, Y.

Subjects
Adult, Male, Adolescent, Biochemistry, Immunology, Hematology, Cell Biology, Interferon-alpha, DNA Methylation, Genes, abl, Middle Aged, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Humans, Hydroxyurea, Female, Child, Promoter Regions, Genetic, Aged, Follow-Up Studies
Abstract

We previously reported that the abl promoter (Pa) undergoes de novo DNA methylation in the course of chronic myelocytic leukemia (CML). The clinical implications of this finding are the subject of the present study in which samples of CML patients, including a group treated with interferon alpha (IFNalpha) were surveyed. The methylation status of the abl promoter was monitored by polymerase chain reaction (PCR) amplification of the Pa region after digestion with several site-methylation sensitive restriction enzymes. Some 74% of the DNA samples from blood and marrow drawn in the chronic phase were nonmethylated, similar to control samples from non-CML patients. The remaining 26% were partially methylated in the abl Pa region. The latter samples were derived from patients who were indistinguishable from the others on the basis of clinical presentation. Methylated samples were mostly derived from patients known to have a disease of longer duration (26 months v 7.5 months, P = .01). Samples of 30 IFNalpha-treated patients were sequentially analyzed in the course of treatment. Fifteen patients with no evidence of Pa methylation before treatment remained methylation-free. The remainder, who displayed Pa methylation before treatment, reverted to the methylation-free status. The outcome is attributed to IFNalpha therapy, as the Pa methylation status was not reversed in any of the patients treated with hydroxyurea. Methylation of the abl promoter indicates a disease of long-standing, most likely associated with a higher probability of imminent blastic transformation. It appears to predict the outcome of IFNalpha therapy far better than the cytogenetic response.

Published
1997

34. Hepatic iron overload: quantitative MR imaging.

Author

Gomori, J M, primary, Horev, G, additional, Tamary, H, additional, Zandback, J, additional, Kornreich, L, additional, Zaizov, R, additional, Freud, E, additional, Krief, O, additional, Ben-Meir, J, additional, Rotem, H, additional, Kuspet, M, additional, Rosen, P, additional, Rachmilewitz, E L, additional, and Gorodetsky, R, additional

Published
1991
Full Text
View/download PDF

40. ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.

Author

Shteper, P J, Siegfried, Z, Asimakopoulos, F A, Palumbo, G A, Rachmilewitz, E A, Ben-Neriah, Y, and Ben-Yehuda, D

Subjects
LYMPHOBLASTIC leukemia, METHYLATION
Abstract

In human Ph-positive leukemia there is a clear association of different forms of the BCR-ABL oncogene with distinct types of leukemia. The P190 form of BCR-ABL is rarely observed in chronic myeloid leukemia (CML) but is present in 50% of Ph-positive acute lymphoblastic leukemia (ALL). In contrast, the P210 form is observed both in CML and 50% of Ph-positive ALL. Methylation of the proximal promoter of the ABL1 gene has been shown to be a nearly universal event associated with clinical progression of CML. This raises the question of whether methylation of the ABL1 promoter is an epigenetic modification also associated with Ph-positive ALL. To study this issue, we used methylation-specific PCR and bisulfite sequencing to determine the methylation status of the ABL1 promoter in 18 Ph-positive ALL samples. We report here that gene-specific ABL1 promoter methylation is associated mainly with the P210 form of BCR-ABL and not the P190 form. While six out of the seven P210-positive ALL samples had ABL1 promoter methylation, none of the 11 P190-positive ALL samples demonstrated ABL1 promoter methylation. In addition, we estimated the extent and relative abundance of ABL1 promoter methylation in several Ph-positive ALL samples and compared it to the methylation pattern in chronic, accelerated and blastic crisis phases of CML. We put forth a model that correlates the different types of leukemias with the different levels of ABL1 promoter methylation. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

46. The effect of an antiserotonin agent pizotifen on platelet aggregability in migraine patients.

Author

Mazal, S and Rachmilewitz, E A

Abstract

In 19 patients who were suffering from frequent migraine attacks and were treated with pizotifen, spontaneous platelet aggregation (SPA) was measured prior to treatment and at the second, fourth and sixth month of treatment. A Migraine Headache Score (MHS) was employed for evaluation of the "activity" of migraine in the same periods. Spontaneous platelet aggregation was also measured in a control group of 40 migraine-free subjects. Prior to treatment the mean value of SPA in the group of migraine patients was four times higher than in the control group. In the 19 migraine patients the mean value of SPA in the second month of treatment showed a 48% reduction when compared with the mean value of SPA prior to treatment. Clear clinical improvement was observed during the treatment, and the average MHS in the second month of treatment showed a 77% reduction compared with the average MHS prior to treatment. The increased rate of SPA prior to treatment and the close correlation between the SPA rate and "activity" of migraine during the treatment suggest that increased platelet aggregability may play a significant role in the pathogenesis of migraine. [ABSTRACT FROM AUTHOR]

Published
1980

47. Aseptic cavernous sinus thrombosis after internal carotid arterial occlusion in polycythaemia vera.

Author

Melamed, E, Rachmilewitz, E A, Reches, A, and Lavy, S

Abstract

Two patients with untreated polycythaemia vera developed intracranial internal carotid arterial occlusion followed by monocular blindness and the characteristic features of ipsilateral cavernous sinus thrombosis. Primary septic source and signs of systemic infection were absent. It is suggested that the predisposing factors in this unusual syndrome were hyperviscosity and venous sludging induced by the basic haematological disorder and progression of the thrombotic process within the internal carotid artery towards its intracavernous portion with occlusion of the ophthalmic artery and of the arterial branches which supply the walls of the sinus. [ABSTRACT FROM AUTHOR]

Published
1976

Catalog

Books, media, physical & digital resources
See catalog results